Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 7;45(22):2016-2018.
doi: 10.1093/eurheartj/ehae102.

Inhibition of miR-21: cardioprotective effects in human failing myocardium ex vivo

Naisam Abbas  1   2 , Jonas A Haas  1 , Ke Xiao  2 , Maximilian Fuchs  2 , Annette Just  1 , Andreas Pich  3 , Filippo Perbellini  1 , Christopher Werlein  4 , Fabio Ius  5 , Arjang Ruhparwar  5 , Jan Fiedler  2 , Natalie Weber  1 , Thomas Thum  1   6
Affiliations

Inhibition of miR-21: cardioprotective effects in human failing myocardium ex vivo

Naisam Abbas et al. Eur Heart J. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
miR-21 inhibition results in cardioprotective effects in human heart failure LMS. (A) Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) quantification of miR-21-5p in fresh untreated LMS and LMS treated with either LNA-ctrl or LNA-antimiR-21 (100 nM) for 96 h, normalized to RNU48 (*P < .05, **P < .01; one-way analysis of variance (ANOVA); bio n = 5, LMS n = 7–9). Data are displayed as mean ± SEM. (B) LDH quantification in the supernatant of LMS treated with LNA-ctrl or LNA-antimiR-21 (100 nM) for 96 h (*P < .05; Student’s t-test; bio n = 3, LMS n = 3). Data are displayed as mean ± SEM. (C) Half relaxation time (50% relaxation time, in msec) of LNA-ctrl and LNA-antimiR-21 treated LMS based on recordings obtained from biomimetic cultivation chambers (*P < .05; Student’s t-test; bio n = 5, LMS n = 6–7). Data are displayed as mean ± SEM. (D) Demographics, clinical characteristics, and concomitant medication of the enrolled patients. *patient 2 received levosimendan and bisoprolol as chronic treatment. The treatment was stopped two to three months before heart transplantation. M = male, F = female, DCM = dilated cardiomyopathy, ICM = ischaemic cardiomyopathy. LV-EF = left ventricular ejection fraction in %. (E) Heatmap of RNA-seq analysis illustrating top 150 differentially expressed genes—ranked by the mean difference between the groups: LNA-ctrl and LNA-antimiR-21. Bio n = 5, LMS n = 5; |Log₂FC|>0.5; P < .05); colour scaling shows the levels for a given gene, blue—up-, red—downregulated. (F) Volcano plot of RNA-seq dataset. X-axis: log2(fold change), Y-axis: -log(P-value). Top differentially expressed genes (DEGs) are highlighted. (G) Functional enrichment analysis of RNA-seq data. Selected clusters from different databases are included. X-axis—Normalized enrichment score LNA-antimiR-21 vs. LNA-control. False discovery rate (FDR) <.05.
See this image and copyright information in PMC

References

    1. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. . MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980–4. 10.1038/nature07511 - DOI - PubMed
    1. Hinkel R, Ramanujam D, Kaczmarek V, Howe A, Klett K, Beck C, et al. . AntimiR-21 prevents myocardial dysfunction in a pig model of ischemia/reperfusion injury. J Am Coll Cardiol 2020;75:1788–800. 10.1016/j.jacc.2020.02.041 - DOI - PubMed
    1. Fischer C, Milting H, Fein E, Reiser E, Lu K, Seidel T, et al. . Long-term functional and structural preservation of precision-cut human myocardium under continuous electromechanical stimulation in vitro. Nat Commun 2019;10:532. 10.1038/s41467-018-08003-1 - DOI - PMC - PubMed
    1. Cavarretta E, Condorelli G. miR-21 and cardiac fibrosis: another brick in the wall? Eur Heart J 2015;36:2139–41. 10.1093/eurheartj/ehv184 - DOI - PubMed
    1. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015;4:e05005. 10.7554/eLife.05005 - DOI - PMC - PubMed

Grants and funding